Wits University Plays Pivotal Role in Global SNAP Trial on Golden Staph Treatment

The University of the Witwatersrand, commonly known as Wits University, has made a significant contribution to one of the largest international clinical trials ever conducted on Staphylococcus aureus bloodstream infections, often referred to as golden staph. Through its Clinical Health Research Unit, Wits served as the sole low- and middle-income country participant in the Staphylococcus aureus Network Adaptive Platform Trial, or SNAP Trial. This involvement highlights the growing capacity of South African universities to lead and support high-impact medical research that addresses global health challenges.

Understanding Golden Staph and Its Impact in South Africa

Golden staph, scientifically known as Staphylococcus aureus, is a common bacterium that lives on the skin and in the noses of many people without causing harm. When it enters the bloodstream, however, it can lead to severe infections with mortality rates between 15 and 25 percent. South Africa faces a particularly high burden of these infections due to factors such as limited healthcare resources in some areas and higher rates of underlying conditions that increase vulnerability. The disease causes over one million deaths worldwide each year, with low- and middle-income countries like South Africa bearing a disproportionate share.

The SNAP Trial: An Adaptive Platform Approach to Antibiotic Research

The SNAP Trial represents a major advance in clinical research methodology. As an adaptive platform trial, it allows researchers to evaluate multiple treatment options simultaneously and adjust the study design based on emerging data. Led primarily by institutions in Australia, the trial involved more than 150 hospitals across 14 countries. South African participation through Wits University added critical diversity to the participant pool, ensuring findings are relevant beyond high-income settings.

Wits researchers enrolled 28 participants at Helen Joseph Hospital in Johannesburg between August 2023 and May 2025, achieving a remarkable 100 percent follow-up completion rate. This success demonstrates that rigorous clinical trials can be conducted effectively in resource-constrained environments.

Key Findings from the Landmark Publications

Results published in June 2026 in two of the world's leading medical journals challenge long-standing treatment practices. The New England Journal of Medicine study compared cefazolin and flucloxacillin for methicillin-susceptible Staphylococcus aureus infections. Cefazolin proved at least as effective while causing fewer side effects and lower rates of kidney injury. A companion study in The Lancet examined benzylpenicillin versus flucloxacillin for penicillin-susceptible strains and reached similar conclusions about safety and efficacy.

These outcomes suggest that flucloxacillin, previously considered the default option in many settings, should no longer serve as the first-line treatment in all cases. Instead, clinicians can select from safer alternatives guided by laboratory testing for penicillin susceptibility.

Photo by Logan Voss on Unsplash

Implications for Clinical Practice in South African Hospitals

The trial results carry direct relevance for South African healthcare. With high rates of golden staph bloodstream infections, local hospitals stand to benefit from updated protocols that reduce complications such as kidney damage. Implementation will require collaboration between universities, the Department of Health, and regulatory bodies to update treatment guidelines and ensure availability of recommended antibiotics.

Dr. Tom Boyles, Senior Researcher at Wits' Clinical Health Research Unit, noted that the findings will benefit South African patients directly while reinforcing the value of including diverse populations in global studies.

Strengthening Research Capacity at South African Universities

Wits University's involvement in the SNAP Trial underscores the importance of investing in clinical research infrastructure within higher education institutions. Participation has built local expertise in adaptive trial design, data management, and patient follow-up. Such experiences prepare the next generation of researchers and clinicians for careers in evidence-based medicine.

South African universities like Wits, the University of Cape Town, and Stellenbosch University continue to expand their roles in international collaborations. These efforts align with national priorities to enhance research output and address pressing health issues through rigorous scientific inquiry.

Training the Next Generation of Medical Researchers

Clinical trials such as SNAP provide invaluable training opportunities for postgraduate students and early-career academics at South African institutions. Medical students and PhD candidates gain hands-on experience in trial coordination, ethical considerations, and statistical analysis. This practical exposure complements classroom learning and positions graduates for competitive roles in academia and industry.

Universities across the country are increasingly integrating research methodology into curricula to prepare graduates for a healthcare landscape shaped by evidence from large-scale studies.

Challenges and Opportunities for Low- and Middle-Income Country Participation

While South Africa's inclusion as the only low- and middle-income country site proved successful, broader participation faces hurdles including funding constraints and infrastructure limitations. The ex-gratia support that enabled Wits' involvement highlights the need for sustainable funding models to support future trials.

Nevertheless, the experience demonstrates clear benefits: cost-effective operations, high disease burden providing relevant data, and ethical imperatives to ensure research benefits the populations most affected.

Photo by Dave Adamson on Unsplash

Future Directions for Antibiotic Research and University Partnerships

The SNAP Trial opens doors for expanded research on other bacterial infections and treatment strategies. South African universities are well-positioned to lead or join follow-up studies, particularly those focused on regional antibiotic resistance patterns. Partnerships with international bodies such as the National Health and Medical Research Council of Australia and local entities like the National Research Foundation can accelerate progress.

Continued emphasis on open science and data sharing will further strengthen the global research community.

The Broader Impact on Higher Education in South Africa

Landmark studies like the SNAP Trial elevate the profile of South African higher education on the world stage. They attract international students, foster interdisciplinary collaborations, and demonstrate the societal value of university research. As institutions continue to produce high-quality evidence, they reinforce their role as engines of innovation and improved public health outcomes.